31 results about "Sinoatrial node" patented technology

A percutaneously implantable chamber for the treatment of a cardiac condition is disclosed herein, the chamber capable of delivery and maintenance of viable cells comprising a pacemaker gene or other genes intended to impart a specific function via a host cell. An artificial sinoatrial node and artificial atrial ventricular node for the restoration of the pacemaker function of the heart of a subject comprises a chamber comprising cells expressing a pacemaker gene. Further, a chamber may be used for the implantation and maintenance of viable, responsive, immunoisolated cells to induce or enhance muscle contraction of a subject for the treatment of a disorder.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

Cell transplantation for constructing biological heart pacemaker is used embryo source dry/ancestral cell and adult mesogalia dry cell as cell sources. The process is carried out by oriented differentiation inducing for heart pacemaker cell by embryo source multifunctional dry cell, bone marrow adhering to obtain primary culture cell, clone culturing to obtain purifying system by diluting, applying paracrine factor endothelin-1 or nervous adjusting protein-1, extracellular matrix laminated adherent protein and fiber connecting protein etc. substrate glue, trans-dyeing pacemaker gene HCN4, and in-vitro inducing embryo source multifunctional dry cell. It is various and non-immunogenicity. It can be used to treat sick sinus syndrome.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

Vagal stimulation applied to the atrioventricular nodal (“AVN”) fat pad and the sinoatrial nodal (“SAN”) fat pad via epicardial leads is useful for controlling cardiac arrhythmia, including atrial fibrillation (‘AF”). In the case of AF, for example, vagal stimulation may be applied initially to the AVN fat pad to reduce ventricular rate, and vagal stimulation may be applied to the SAN fat pad after restoration of sinus rhythm to control atrial rate. The technique is applicable to control acute AF and chronic AF. The vagal stimulation may be optimized for exciting ganglia in the fat pads to produce dromotropic and chronotropic effects in the atrioventricular node and the sinoatrial node, respectively. In addition, the SAN fat lead can also be used to pace the atrium in case of sinus bradycardia.

Disclosed herein is a biomagnetic measurement apparatus capable of visualizing cardiac electrical current distributions with information on the cardiac morphology of a subject. A magnetic field component in the z direction, vertical to the chest surface of a subject, is measured from two directions, front and back of the chest, and then to calculate the current distributions in the two directions and the distributions of the amplitudes of those current distributions. A three-dimensional standard heart model is created from average data on the cardiac morphology obtained from plural healthy subjects. An optimal position of the model is determined using the coordinates of the sinus node and the coordinates of the left ventricle. Then, a weight coefficient is obtained by front and back current distributions and front and back the distributions of the amplitudes of those current distributions on a set boundary of the model.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the left stellate ganglion, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering anti-arrhythmic therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of anti-arrhythmic therapy include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenyloin, carbamazepine, valproate, and phenobarbitone.

The invention provides a conducting-wire-free pacemaker and a conducting-wire-free pacing system. The conducting-wire-free pacemaker uses an umbrella-shaped structural design, and comprises a conducting-wire-free pacing device positioned on the umbrella handle and a support device positioned on the umbrella surface; the support device can fix the conducting-wire-free pacing device onto a specifiedposition; side effects caused by a conventional electrode conducting wire are eliminated. Meanwhile, compared with other conducting-wire-free pacemakers used for the ventriculus dexter (particularlyright ventricular apex), the conducting-wire-free pacemaker has the advantages that the umbrella-shaped structure is used, so that the contact area with the heart tissue is greater; the fixation stability is higher, so that the conducting-wire-free pacemaker can be used in a position of auricula dextra near the sinoatrial node, the pacing sequence better conforming to the physiologic performance can be provided, and the harm to the heart is reduced accordingly. The conducting-wire-free pacing system provided by the invention uses the conducting-wire-free pacemaker; a special conveyor and a guide device are configured for the conducting-wire-free pacemaker, so that the implementation of the conducting-wire-free pacemaker becomes more convenient and more precise.

The invention relates to a direct heart-assist device based on an artificial muscle network, wherein the artificial muscle network consists of artificial muscle units and is provided with an extractor of atrionector heart rhythm, a contraction and diastole process controller and a current drive device. Each artificial muscle unit is formed by combining a shape memory alloy wire inner-layer spring and a heat-conducting wire, wherein each heat-conducting wire is arranged at the center of the corresponding shape memory alloy wire inner-layer spring, a layer of thin film is arranged outside each shape memory alloy wire inner-layer spring and is used for preventing double-layer springs from mutually locking in a clamping manner, the outmost layer is a pressure spring with the certain K value and a sealed shell, and the two ends of each shape memory alloy wire inner-layer spring are connected with an inner shape memory alloy wire, thus the shape memory alloy wires are stretched at a normal state and the artificial muscle units are linked to form a network covering outside a heart so as to form the direct heat-assist device based on the artificial muscle network. The current drive device outputs to the shape memory alloy wires of the artificial muscle units.

A device for electrical stimulation of the brain, heart, and other neurons and muscles, capable of modifying the electrical activity of its environment in ways that are desirable for a better life style of a patient with brain, heart, or other problems. When used for brain stimulation, the device is able to superimpose an electrical current on the natural current that happens to occur, when the natural currents cause some undesirable effect, as in Parkinson's disease. When used for heart stimulation, the device is able to superimpose an electrical current on the natural current that happens to occur, originating at the sino-atrial node, which causes a healthy heart to pump blood to the lungs and to the body. The device offers an improvement over prior art of being capable of adjusting the position of the stimulating electrodes.

The invention relates to the technical field of medical instruments, and discloses a cardiology department nursing heart pace-making monitoring device, which comprises a shell, outer membranes are fixedly connected to the upper end and the lower end of the shell, tripods are fixedly connected to the inner walls of the upper side and the lower side of the shell, and inner membranes are fixedly connected to the middles of the tripods; and a movable block is fixedly connected to the side, close to the center of the shell, of the inner film. According to the cardiology department nursing heart pace-making monitoring device, when the blood pressure in the atrium rises, the outer membrane is compressed and amplified through the inner membrane to change the position of the movable block to enable the pressurizing block to move, the first plug bodies get away from each other to increase the discharging frequency of the capacitor plate, and meanwhile the second plug bodies move to increase the intensity of pulse current to prevent excessive hydrops in the atrium; adn then current generated autonomously through sinus node and pulse current of the pacemaker enter the upper side electromagnet and the lower side electromagnet respectively; therefore, the second contact is disconnected when the magnetic field is balanced, the pacemaker stops working and the phenomenon of pacing dependence of a patient is prevented.

A zero flow responsive heart stimulator contains a zero flow sensors, which generate signals at the moment of the termination of blood inflow in the right atrium and the right ventricle, sensing this the most precisely in the places, where the sinoatrial node and atrioventricular node reside, for the right atrium and the right ventricle, respectively. The stimulator is based on our discovery, that the two nodes are the same sensors in the biological systems, based on the fact that until the filling of the said two chambers continues, the venous blood flow sucks on Bernoulli's principle the Ca and Na cations from the two nodes interstices, preventing the inward currant in their cells, thus delaying the completion of the 0-phase of their depolarization and the action potential, until the blood flow stops. Our discovery proves that the alternating flow/no flow of the blood in the orifice of superior vena cava and the entrance of the right ventricle is the real pacemaker that fires the both nodes, but not the inverse, as generally assumed, approximating the natural pacemaker to a clock mechanism. This, together with the discovered by us arteriovenous, arteriolymphatic and capillary pumps, closes the loop of the autonomous automatic functioning of the cardiovascular system, even completely denervated and in the absence of muscle contractions. It is the first devise, which activates the atrial and the ventricular contractions in a function of the zero-flow of the filling them venous blood, which is the exact imitation of the sinoatrial and atrioventricular firing.

The invention discloses a method for constructing virtual physiological tissues of a sinus node, a storage medium and a computing device. The method comprises the following steps: creating a geometricmodel for the virtual physiological tissues of a sinus; dividing the geometric model into a plurality of areas including a non-excited tissue area, a central sinus node tissue area, a peripheral sinus node tissue area and an atrium tissue area; respectively constructing corresponding cell models for the non-excited tissues, the central sinus node tissues, the peripheral sinus node tissues and theatrium tissues; and respectively constructing electrical excitation conduction models for the non-excited tissues, the central sinus node tissues, the peripheral sinus node tissues and the atrium tissues obtained after the division. The virtual physiological tissues constructed by the method of the invention construct a bridge for changing from microscopic molecules to macroscopic organ, recurring sinus node pace-making and electrical conduction processes are in line with the electrophysiology of the human sinus node, the time and money cost of animal experiments is reduced, and the pace-making mechanism of the sinus node can be fast, well and safely studied.

The invention provides an artery hardness monitoring method and device. The method comprises the following steps: determining a first conduction time difference between a first conduction path and a second conduction path of a pulse wave; wherein the first conduction path refers to a path from a sinus node pace-making point to a heart ejection point and then from the heart ejection point to a first measurement point, and the second conduction path refers to a path from the sinus node pace-making point to the heart ejection point and then from the heart ejection point to a second measurement point; determining a first path difference between the first conduction path and the second conduction path; determining a pulse wave conduction velocity at least according to the first conduction time difference and the first path difference; wherein the pulse wave conduction velocity is used for reflecting the arterial blood vessel hardening degree.

The invention relates to a precise positioning and material taking method of adult rat atrionector. According to the method, the rat atrionector is macroscopically positioned in the proximal part wall of the precava and extends into a junctional zone of the right atrium and the precava, and after the right precava is marked by a body suturing knotting method, the rat heart is taken down along the far end of the precava. The invention also relates to a naked eye precise positioning method of the serial section of the adult rat atrionector. The atrionector subjected to material taking is subjected to the serial section after the fixation, the position and the form of the atrionector on the precava wall is simultaneously observed in the section process through naked eyes, and the atrionector is precisely positioned.

A method for detecting heart rhythm irregularities, including the steps of: measuring pulse peaks continuously over a period of time to obtain pulse peak sequence and pulse peak time interval sequence corresponding to the pulse peak sequence; and calculating the absolute value of a difference between a single pulse peak time interval in the pulse peak time interval sequence and an average value of the pulse peak time interval sequence, and determining that an irregular pulse peak (IPP) has occurred if the absolute value is larger than or equal to 15% to 25% of the average value of the pulse peak time interval sequence. A detection device using the method is also provided. This uses a non-invasive approach to detect heart rhythm irregularities such as sick sinus syndrome, irregular pulse peaks, irregular heartbeat, and atrial fibrillation, and can be applied to a sphygmomanometer or a wearable device.

A method of creating an atrioventricular bypass tract for a heart comprises growing mesenchymal stem cells into a strip with two ends, attaching one end of the strip onto the atrium of the heart, and attaching the other end of the strip to the ventricle of the heart, to create a tract connecting the atrium to the ventricle to provide a path for electrical signals generated by the sinus node to propagate across the tract and excite the ventricle.

The current application relates to compounds that bind and inhibit the inactivation of Navi.5 voltage-gated sodium channel (VGSC). The compounds can be used for treating cardiovascular diseases such as Brugada syndrome, cardiac arrhythmia disorder, progressive cardiac conduction disorder (PCCD), sick sinus syndrome, progressive familial block, atrial fibrillation, sudden infant death syndrome, dilated cardiomyopathy, myocardial ischemia/infarction, or heart failure.

The invention discloses a traditional Chinese medicine composition for treating sick sinus syndrome, coronary heart disease angina and arrhythmia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from musk, venenum bufonis, bezoar, borneol, red ginseng, pseudo-ginseng, amber, the root of red-rooted salvia and storax. According to the theory of traditional Chinese medicine of syndrome differentiation, the raw materials of the composition are screened by a large number of experiments, are reasonably matched and are complementary, thus jointly realizing the effects of strengthening heart and tonifying qi, and activating yang so as to restore the pulse; the aromatic composition also has effects of inducing resuscitation and activating blood and easing pain, has good curative effect for bradycardia sick sinus syndrome, coronary heart disease angina and arrhythmia, has no toxic or side effects, has a scientific and reasonable preparation method, and realizes large scale industrial production.